AIM ImmunoTech Resolves Equity Deficiency, Regains NYSE Compliance

Event summary

  • AIM ImmunoTech received notice from NYSE American on June 12, 2026, confirming compliance with stockholders’ equity standards.
  • The company resolved a stockholder equity deficiency through a series of transactions totaling approximately $8.5 million in gross proceeds.
  • The “below compliance” (.BC) indicator will be removed from AIM’s trading symbol.
  • AIM issued 10,073,470 shares of common stock and warrants in private placements between May and June 2026.

The big picture

AIM ImmunoTech’s resolution of its equity deficiency and regaining NYSE compliance marks a critical step in stabilizing its financial footing. The company’s ability to secure approximately $8.5 million in gross proceeds through warrant exercises and private placements underscores its ongoing efforts to strengthen governance and maintain market confidence. This development comes amid broader industry trends where biopharmaceutical firms face increasing scrutiny over financial health and regulatory adherence.

What we're watching

Financial Stability
Whether AIM can sustain stockholders’ equity above the $6.0 million minimum requirement.
Regulatory Monitoring
The pace at which NYSE American continues to monitor AIM’s compliance.
Clinical Progress
How Ampligen’s development timeline impacts AIM’s long-term strategic positioning.